ReviewEndocrinology2011
Minireview: steroid receptor coactivator-3: a multifarious coregulator in mammary gland metastasis.
Review in Endocrinology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Article
- Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy.Journal of medicinal chemistry · 2024Article
- Decidualization of human endometrial stromal cells requires steroid receptor coactivator-3.Frontiers in reproductive health · 2022Article
- The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.Nature medicine · 2021Article
- Phosphorylation of steroid receptor coactivator-3 (SRC-3) at serine 857 is regulated by the p38Scientific reports · 2020Article
- Pinning Down the Transcription: A Role for Peptidyl-ProlylFrontiers in cell and developmental biology · 2020Review
- Role for Growth Regulation by Estrogen in Breast Cancer 1 (GREB1) in Hormone-Dependent Cancers.International journal of molecular sciences · 2018Review
- Hyperactivation of nuclear receptor coactivators induces PERK-dependent cell death.Oncotarget · 2018Article
- Corepressor metastasis-associated protein 3 modulates epithelial-to-mesenchymal transition and metastasis.Chinese journal of cancer · 2017Review
- NCOA3 coactivator is a transcriptional target of XBP1 and regulates PERK-eIF2α-ATF4 signalling in breast cancer.Oncogene · 2016Article
- The p160/steroid receptor coactivator family: potent arbiters of uterine physiology and dysfunction.Biology of reproduction · 2014Review
- MicroRNA-195 regulates steroid receptor coactivator-3 protein expression in hepatocellular carcinoma cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Cell proliferation and apoptosis in rat mammary glands following combinational exposure to bisphenol A and genistein.BMC cancer · 2014Article
- Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer.Oncotarget · 2014Review
- Identification of verrucarin a as a potent and selective steroid receptor coactivator-3 small molecule inhibitor.PloS one · 2014Article
- Nuclear receptors in bone physiology and diseases.Physiological reviews · 2013Review
- AIB1 cooperates with ERα to promote epithelial mesenchymal transition in breast cancer through SNAI1 activation.PloS one · 2013Article
- Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.International journal of molecular sciences · 2012Review
- Expression and function of nuclear receptor co-activator 4: evidence of a potential role independent of co-activator activity.Cellular and molecular life sciences : CMLS · 2012Review
- Nuclear receptor coactivator RAC3 inhibits autophagy.Cancer science · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
A member of the steroid receptor coactivator (SRC)/p160 family, SRC-3 acts as a coregulator for nuclear receptor (NR) and non-NR transcription factors. Such coregulator pleiotropy enables SRC-3 to influence a myriad of signaling networks that are essential for normal physiology and pathophysiology. Although SRC-3's proliferative role in primary tumor formation in the mammary gland is well established, a role for this oncogenic coregulator in tumor cell motility and invasion has only recently been elucidated. In the nucleus, SRC-3 is required for the execution of the epithelial-mesenchymal transition, a programming step which endows an immotile cancer cell with motile and invasive characteristics. Nuclear SRC-3 is also essential for proteolytic breakdown of the extracellular matrix by matrix-metalloproteinases, a process which enables primary tumor cell invasion into the surrounding stroma. At the plasma membrane, however, a truncated isoform of SRC-3 (SRC-3Δ4) serves as a signaling adaptor for the epidermal growth factor→focal adhesion kinase→c-Src signal transduction pathway, a signaling cascade that is central to growth factor-induced cell migration and invasion. Together, these studies underscore a pivotal role for SRC-3 not only as a proto-oncogene but also as a prometastatic factor during the early steps in the invasion-metastasis cascade. Beyond furnishing critical mechanistic insights into SRC-3's involvement in mammary tumor progression, these findings provide opportunities to develop new approaches for breast cancer diagnosis and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.